| 1 |
Studentova H, Rusarova N, Ondruskova A, Zemankova A, Student V, Skanderova D, Melichar B. The Role of Cytoreductive Nephrectomy in Renal Cell Carcinoma with Sarcomatoid Histology: A Case Series and Review of the Literature. Current Oncology 2022;29:5475-5488. [DOI: 10.3390/curroncol29080433] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 2 |
Patel HD, Man A, Koehne EL, Rac G, Aragao AP, Flanigan RC, Gorbonos A, Gupta GN, Woods ME, Picken MM, Quek ML. Percentage of sarcomatoid histology is associated with survival in renal cell carcinoma: Stratification and implications by clinical metastatic stage. Urologic Oncology: Seminars and Original Investigations 2022;40:347.e1-347.e8. [DOI: 10.1016/j.urolonc.2022.04.003] [Reference Citation Analysis]
|
| 3 |
Alnajar H, Ravichandran H, Figueiredo Rendeiro A, Ohara K, Al Zoughbi W, Manohar J, Greco N, Sigouros M, Fox J, Muth E, Angiuoli S, Faltas B, Shusterman M, Sternberg CN, Elemento O, Mosquera JM. Tumor-immune microenvironment revealed by Imaging Mass Cytometry in a metastatic sarcomatoid urothelial carcinoma with a prolonged response to pembrolizumab. Cold Spring Harb Mol Case Stud 2022;8. [PMID: 35483877 DOI: 10.1101/mcs.a006151] [Reference Citation Analysis]
|
| 4 |
Bersanelli M, Casartelli C, Buti S, Porta C. Renal cell carcinoma and viral infections: A dangerous relationship? World J Nephrol 2022; 11(1): 1-12 [DOI: 10.5527/wjn.v11.i1.1] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 5 |
Bialek J, Wencker A, Kawan F, Yankulov S, Fornara P, Theil G. Potential Use of CTCs as Biomarkers in Renal Cancer Patients. Life (Basel) 2022;12:89. [PMID: 35054482 DOI: 10.3390/life12010089] [Reference Citation Analysis]
|
| 6 |
Magi-galluzzi C, Fatima H, Duncan VE, Zhou M. Ureter, Urinary Bladder, and Kidney. Gattuso's Differential Diagnosis in Surgical Pathology 2022. [DOI: 10.1016/b978-0-323-66165-2.00010-7] [Reference Citation Analysis]
|
| 7 |
Candelario N, Geiger C, Flaig T. Sarcomatoid Renal Cell Carcinoma: The Present and Future of Treatment Paradigms. KCA 2021;5:167-79. [DOI: 10.3233/kca-210126] [Reference Citation Analysis]
|
| 8 |
Agaimy A, Hartmann A, Trpkov K, Hes O. Undifferentiated and dedifferentiated urological carcinomas: lessons learned from the recent developments. Semin Diagn Pathol 2021;38:152-62. [PMID: 34579992 DOI: 10.1053/j.semdp.2021.09.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 9 |
Dumond A, Montemagno C, Vial V, Grépin R, Pagès G. Anti-Vascular Endothelial Growth Factor C Antibodies Efficiently Inhibit the Growth of Experimental Clear Cell Renal Cell Carcinomas. Cells 2021;10:1222. [PMID: 34067671 DOI: 10.3390/cells10051222] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 10 |
Fu Y, Wang PP, He D, Zheng Y, Ding ZY. Major pathological response after neoadjuvant immunotherapy in esophageal spindle cell carcinoma: A case report. Thorac Cancer 2021;12:1234-9. [PMID: 33619875 DOI: 10.1111/1759-7714.13905] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 11 |
Adashek JJ, Zhang Y, Skelton WP 4th, Bilotta A, Chahoud J, Zemp L, Li J, Dhillon J, Manley B, Spiess PE. Dissecting Outcomes: Should Cytoreductive Nephrectomy Be Performed for Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation? Front Oncol 2020;10:627025. [PMID: 33643921 DOI: 10.3389/fonc.2020.627025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 12 |
Numakura K, Kobayashi M, Muto Y, Sekine Y, Takahashi M, Kashima S, Yamamoto R, Koizumi A, Nara T, Saito M, Narita S, Nanjyo H, Habuchi T. First-line axitinib therapy is less effective in metastatic renal cell carcinoma with spindle histology. Sci Rep 2020;10:20089. [PMID: 33208816 DOI: 10.1038/s41598-020-77135-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 13 |
Moch H, Ohashi R. Chromophobe renal cell carcinoma: current and controversial issues. Pathology 2021;53:101-8. [PMID: 33183792 DOI: 10.1016/j.pathol.2020.09.015] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 14 |
Iacovelli R, Ciccarese C, Bria E, Bracarda S, Porta C, Procopio G, Tortora G. Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors. Eur J Cancer 2020;136:195-203. [PMID: 32712550 DOI: 10.1016/j.ejca.2020.06.008] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 10.7] [Reference Citation Analysis]
|
| 15 |
Montironi R, Cimadamore A, Ohashi R, Cheng L, Scarpelli M, Lopez-Beltran A, Moch H. Chromophobe Renal Cell Carcinoma Aggressiveness and Immuno-oncology Therapy: How to Distinguish the Good One from the Bad One. Eur Urol Oncol 2021;4:331-3. [PMID: 32199916 DOI: 10.1016/j.euo.2020.02.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 16 |
Cimadamore A, Cheng L, Ohashi R, Scarpelli M, Lopez-Beltran A, Moch H, Montironi R. Re: Multi-institutional Re-evaluation of Prognostic Factors in Chromophobe Renal Cell Carcinoma: Proposal of a Novel Two-tiered Grading Scheme. Eur Urol 2020;78:114-6. [PMID: 32143925 DOI: 10.1016/j.eururo.2020.02.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 17 |
Manini C, López JI. The Labyrinth of Renal Cell Carcinoma. Cancers (Basel) 2020;12:E521. [PMID: 32102400 DOI: 10.3390/cancers12020521] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
|
